Document Detail

Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group.
MedLine Citation:
PMID:  10841227     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We sought to determine whether the clinical effects of early angiotensin-converting enzyme (ACE) inhibitor (ACEi) treatment for acute myocardial infarction (MI) are influenced by the concomitant use of aspirin (ASA). BACKGROUND: Aspirin and ACEi both reduce mortality when given early after MI. Aspirin inhibits the synthesis of vasodilating prostaglandins, and, in principle, this inhibition might antagonize some of the effects of ACEi. But it is uncertain whether, in practice, this influences the effects of ACEi on mortality and major morbidity after MI. METHODS: This overview sought individual patient data from all trials involving more than 1,000 patients randomly allocated to receive ACEi or control starting in the acute phase of MI (0-36 h from onset) and continuing for four to six weeks. Data on concomitant ASA use were available for 96,712 of 98,496 patients in four eligible trials (and for none of 1,556 patients in the one other eligible trial). RESULTS: Overall 30-day mortality was 7.1% among patients allocated to ACEi and 7.6% among those allocated to control, corresponding to a 7% (standard deviation [SD], 2%) proportional reduction (95% confidence interval 2% to 11%, p = 0.004). Angiotensin-converting enzyme inhibitor was associated with similar proportional reductions in 30-day mortality among the 86,484 patients who were taking ASA (6% [SD, 3%] reduction) and among the 10,228 patients who were not (10% [SD, 5%] reduction: chi-squared test of heterogeneity between these reductions = 0.4; p = 0.5). Angiotensin-converting enzyme inhibitor produced definite increases in the incidence of persistent hypotension (17.9% ACEi vs. 9.4% control) and of renal dysfunction (1.3% ACEi vs. 0.6% control), but there was no good evidence that these effects were different in the presence or absence of ASA (chi-squared for heterogeneity = 0.4 and 0.0, respectively; both not significant). Nor was there good evidence that the effects of ACEi on other clinical outcomes were changed by concomitant ASA use. CONCLUSIONS: Both ASA and ACEi are beneficial in acute MI. The present results support the early use of ACEi in acute MI, irrespective of whether or not ASA is being given.
R Latini; G Tognoni; A P Maggioni; C Baigent; E Braunwald; Z M Chen; R Collins; M Flather; M G Franzosi; J Kjekshus; L Køber; L S Liu; R Peto; M Pfeffer; F Pizzetti; E Santoro; P Sleight; K Swedberg; L Tavazzi; W Wang; S Yusuf
Related Documents :
20581017 - Cardiovascular risk factors in primary sjögren's syndrome: a case-control study in 624...
16722967 - Survival and mortality of myotonic dystrophy type 1 (steinert's disease) in the populat...
7778627 - The accuracy of antenatal fetal echocardiography screening in high- and low-risk patients.
17904457 - Obesity paradox in patients with hypertension and coronary artery disease.
23881157 - Neurological soft signs and brainstem morphology in first-episode schizophrenia.
20981207 - Halimeter ppb levels as the predictor of erosive gastroesophageal reflux disease.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of the American College of Cardiology     Volume:  35     ISSN:  0735-1097     ISO Abbreviation:  J. Am. Coll. Cardiol.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-06-27     Completed Date:  2000-06-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8301365     Medline TA:  J Am Coll Cardiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1801-7     Citation Subset:  AIM; IM    
Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Aspirin / therapeutic use*
Cyclooxygenase Inhibitors / therapeutic use*
Drug Therapy, Combination
Myocardial Infarction / drug therapy*,  mortality
Time Factors
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Cyclooxygenase Inhibitors; 50-78-2/Aspirin
Comment In:
J Am Coll Cardiol. 2000 Jun;35(7):1808-12   [PMID:  10841228 ]
J Am Coll Cardiol. 2001 Apr;37(5):1474-5   [PMID:  11300465 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Risk stratification in unstable coronary artery disease--exercise test and troponin T from a gender ...
Next Document:  Prognostic significance of ST segment depression in lateral leads I, aVL, V5 and V6 on the admission...